Get the Stockscreener App
1.09
3.54%
-0.04
Lisata Therapeutics Inc stock is traded at $1.09, with a volume of 23,936.
It is down -3.54% in the last 24 hours and down -70.62% over the past month.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
See More
Previous Close:
$1.13
Open:
$1.1
24h Volume:
23,936
Relative Volume:
0.22
Market Cap:
$9.82M
Revenue:
$170.00K
Net Income/Loss:
$-16.35M
P/E Ratio:
-0.5859
EPS:
-1.8605
Net Cash Flow:
$-13.66M
1W Performance:
+2.83%
1M Performance:
-70.62%
6M Performance:
-76.15%
1Y Performance:
-57.42%
1-Day Range:
$1.05
$1.15
1-Week Range:
$1.02
$1.2794
52-Week Range:
$0.9875
$5.07
Lisata Therapeutics Inc Stock (LSTA) Company Profile
Name
Lisata Therapeutics Inc
Sector
Industry
Phone
908-229-2590
Address
110 ALLEN ROAD, BASKING RIDGE
Compare LSTA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
1.09 | 10.63M | 170.00K | -16.35M | -13.66M | -1.8605 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lisata Therapeutics Inc Stock (LSTA) Latest News
Enterprise value to EBITDA forward of Lisata Therapeutics, Inc. – FWB:8NE - TradingView
Enterprise value to EBITDA forward of Lisata Therapeutics, Inc. – SWB:8NE - TradingView
Enterprise value to EBIT forward of Lisata Therapeutics, Inc. – NASDAQ:LSTA - TradingView
Lisata Therapeutics (8NE) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Lisata Therapeutics Inc. (NASDAQ: LSTA) Share Price, LSTA Stock News, LSTA Share Price & Updates - Kalkine
LISATA THERAPEUTICS, INC. 2026: Revenue $0 EPS ($0.32) — 10-Q Summary - TradingView
Lisata Therapeutics Announces Major Workforce Reduction and Retrenchment - The Globe and Mail
Lisata Therapeutics sues Kuva Labs, cuts 72% of workforce By Investing.com - Investing.com India
Lisata Therapeutics sues Kuva Labs, cuts 72% of workforce - Investing.com
Lisata Therapeutics, Inc. Continues to Evaluate Strategic Alternatives to Enhance Stockholder Value - marketscreener.com
Lisata Therapeutics (LSTA) Pursues Legal Action After Merger Ter - GuruFocus
Lisata Therapeutics, Inc. (LSTA) Files 8-K Announcing Retention Bonus Agreement With James Nisco - Minichart
Lisata Therapeutics Files Suit Against Kuva Labs, Reviews Strategic Alternatives and Cuts Workforce to Preserve Cash - Quiver Quantitative
Lisata Therapeutics, Inc. Implements a Reduction in Force, Eliminating Approximately 72% of Full-Time Employees - marketscreener.com
Lisata Therapeutics terminates Dr. Kristen K. Buck as EVP R&D & CMO; James Nisco awarded $200,000 retention bonus - TradingView
Lisata Therapeutics moves forward with legal action following Kuva merger termination - Proactive financial news
Lisata sues Kuva Labs after merger deal ends, c... - Pluang
Lisata Therapeutics, Inc. Revenue Breakdown – NASDAQ:LSTA - TradingView
Kuva Labs (LSTA) ends Lisata cash-and-CVR tender offer after financing shortfall - Stock Titan
Lisata Therapeutics Inc (LSTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lisata Therapeutics Inc (LSTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lisata Therapeutics (LSTA) Terminates Merger Agreement with Kuva Labs Amid Financing Issues - GuruFocus
LSTA|Lisata Therapeutics Inc|Price:1.470|Chg%:-0.200 - TradingKey
Lisata Therapeutics Inc (LSTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lisata Therapeutics Inc (LSTA) Cash Flow - TradingKey
Lisata Therapeutics Inc (LSTA) Institutional Confidence - TradingKey
TradingKey - TradingKey
Lisata Therapeutics (LSTA) Plunges 21%: Key Levels to WatchZero Gamma Level - po-news-eg.net
Lisata Therapeutics Ends Kuva Merger, Starts Strategic Review - The Globe and Mail
Lisata Therapeutics, Inc. Revenue Breakdown – LS:A3DWGC - TradingView
Lisata Therapeutics Shares Fall After Terminating Kuva Labs Deal - Moomoo
Lisata Therapeutics Terminates Merger Agreement With Kuva Labs On July 24, Says SEC Filing - TradingView
Lisata Therapeutics Stock Falls After Hours: Here's Why - webull.com
Lisata Therapeutics Inc (LSTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lisata Therapeutics (LSTA) says Kuva tender meets conditions but financing not yet secured - Stock Titan
Kuva Labs, Inc. completed the acquisition of Lisata Therapeutics, Inc.. - marketscreener.com
Lisata Therapeutics (LSTA) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Enterprise value to EBIT forward of Lisata Therapeutics, Inc. – LSE:0HS8 - TradingView
Lisata Therapeutics Amends Merger Agreement with Kuva Labs—Key Details from Latest 8-K Filing - Minichart
Enterprise value to EBITDA forward of Lisata Therapeutics, Inc. – LSE:0HS8 - TradingView
Lisata Therapeutics Extends Merger Timeline with Kuva Labs - TipRanks
Lisata Therapeutics, Kuva Labs Amend Merger Agreement to Extend Outside Date to July 21 - TradingView
Lisata (Nasdaq: LSTA) merger timeline with Kuva pushed to July 21 - Stock Titan
Lisata Therapeutics (LSTA) extends Kuva tender offer as 64.7% of shares tendered - Stock Titan
Lisata Therapeutics (LSTA) tender offer extended as Kuva reports 64.67% tendered - Stock Titan
Lisata Therapeutics (LSTA) extends $4 cash-plus-CVR tender to July 16 - Stock Titan
Lisata Therapeutics (LSTA) Edges Higher: Navigating Support and Resistance LevelsSystematic Flow - dars.gov.et
Lisata Therapeutics (LSTA) holders see Kuva offer extended as over 5.1M shares tendered - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Price to sales forward of Lisata Therapeutics, Inc. – NASDAQ:LSTA - TradingView
Enterprise value to revenue forward of Lisata Therapeutics, Inc. – NASDAQ:LSTA - TradingView
Lisata Therapeutics Inc Stock (LSTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):